[go: up one dir, main page]

WO2003035892A3 - Novel methods for introducing molecules into cells and vectors and compositions for use in such methods - Google Patents

Novel methods for introducing molecules into cells and vectors and compositions for use in such methods Download PDF

Info

Publication number
WO2003035892A3
WO2003035892A3 PCT/US2002/033305 US0233305W WO03035892A3 WO 2003035892 A3 WO2003035892 A3 WO 2003035892A3 US 0233305 W US0233305 W US 0233305W WO 03035892 A3 WO03035892 A3 WO 03035892A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
vectors
compositions
chimeric
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/033305
Other languages
French (fr)
Other versions
WO2003035892A9 (en
WO2003035892A2 (en
Inventor
Peter Ghazal
Dennis R Burton
Klaus M Hahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Priority to EP02802161A priority Critical patent/EP1436315A2/en
Priority to AU2002356824A priority patent/AU2002356824A1/en
Publication of WO2003035892A2 publication Critical patent/WO2003035892A2/en
Publication of WO2003035892A3 publication Critical patent/WO2003035892A3/en
Publication of WO2003035892A9 publication Critical patent/WO2003035892A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Provided are chimeric molecules (i.e., antibody fusion or fusion protein) comprising a carboxy terminal protein import sequence and an animo terminal cargo region. A preferred chimeric molecule according to the invention is a chimeric molecule in which a protein import sequence (i.e., a HIV tat peptide) is linked to a Fab directed against a viral pathogen, such hCMV. Also provided are nucleic acid molecules encoding the chimeric molecules of the invention, as well as vectors and host cells comprising the nucleic acid molecules. In addition, methods of making, methods of using, and compositions comprising a chimeric molecule of the invention are provided. The vector constructs according to the invention can be employed for intracellular delivery, and particularly, for intracellular immunization.
PCT/US2002/033305 2001-10-19 2002-10-18 Novel methods for introducing molecules into cells and vectors and compositions for use in such methods Ceased WO2003035892A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02802161A EP1436315A2 (en) 2001-10-19 2002-10-18 Novel methods for introducing molecules into cells and vectors and compositions for use in such methods
AU2002356824A AU2002356824A1 (en) 2001-10-19 2002-10-18 Novel methods for introducing molecules into cells and vectors and compositions for use in such methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3931801A 2001-10-19 2001-10-19
US10/039,318 2001-10-19

Publications (3)

Publication Number Publication Date
WO2003035892A2 WO2003035892A2 (en) 2003-05-01
WO2003035892A3 true WO2003035892A3 (en) 2003-07-17
WO2003035892A9 WO2003035892A9 (en) 2003-12-04

Family

ID=21904830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033305 Ceased WO2003035892A2 (en) 2001-10-19 2002-10-18 Novel methods for introducing molecules into cells and vectors and compositions for use in such methods

Country Status (3)

Country Link
EP (1) EP1436315A2 (en)
AU (1) AU2002356824A1 (en)
WO (1) WO2003035892A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126885A1 (en) 2002-11-05 2004-07-01 Cines Douglas B. Delivery vehicle for recombinant proteins
CA2567114A1 (en) * 2004-05-28 2005-12-15 Nanogen, Inc. Nanoscale electronic detection system and methods for their manufacture
TW200732472A (en) 2005-10-21 2007-09-01 Hoffmann La Roche Method for the recombinant expression of a polypeptide
EP2218458A1 (en) * 2009-02-13 2010-08-18 Fondazione Telethon Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
JP5764921B2 (en) * 2009-12-24 2015-08-19 Jnc株式会社 Fusion protein with luminescent activity
SG10202110500TA (en) 2017-06-22 2021-11-29 Catalyst Biosciences Inc Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
WO2020140101A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004686A1 (en) * 1992-08-21 1994-03-03 Biogen, Inc. Tat-derived transport polypeptides
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
WO1994004686A1 (en) * 1992-08-21 1994-03-03 Biogen, Inc. Tat-derived transport polypeptides

Also Published As

Publication number Publication date
EP1436315A2 (en) 2004-07-14
WO2003035892A9 (en) 2003-12-04
WO2003035892A2 (en) 2003-05-01
AU2002356824A1 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
WO2002068605A3 (en) Non-oligomerizing tandem fluorescent proteins
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
WO2001068848A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008288A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2715302A (en) Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO2004009768A3 (en) Viral vectors containing recombination sites
WO2002026822A3 (en) Pumpcn compositions and uses thereof
WO2001046420A8 (en) Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
WO2003052118A3 (en) Bgl4 beta-glucosidase and nucleic acids encoding the same
WO2003052054A3 (en) Bgl5 beta-glucosidase and nucleic acids encoding the same
WO2003027306A3 (en) Bgl3 beta-glucosidase and nucleic acids encoding the same
WO2002024888A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1995004151A3 (en) Vaccine compositions containing recombinant tetc-fusion proteins
WO2003052055A3 (en) Egvii endoglucanase and nucleic acids encoding the same
WO2004108938A3 (en) Peptide ligands of dendritic cells for nucleic acid vector targeting
WO1999061469A3 (en) Prostate growth-associated membrane proteins
WO2005000235A3 (en) NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
WO1999060135A8 (en) Generation of multiple gene products from chimeric fusion proteins by cleavage with ubiquitous endoproteases
WO2002074807A3 (en) Chimpanzee erythropoietin (chepo) - immunoadhesins
WO2003035892A3 (en) Novel methods for introducing molecules into cells and vectors and compositions for use in such methods
WO2000068376A8 (en) Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
WO2003103600A3 (en) METHODS AND COMPOSITIONS FOR SYNTHESIS OF NUCLEIC ACID MOLECULES USING MULTIPLE RECOGNITION SITES
WO2002068459A3 (en) Non aggregating fluorescent proteins and methods for using the same
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGE 6/6, SEQUENCE LISTING, ADDED

WWE Wipo information: entry into national phase

Ref document number: 2002802161

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002802161

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2002802161

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002802161

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP